In a statement, Gilead Sciences (NASDAQ:GILD)
Chief Medical Officer Merdad Parsey, M.D., Ph.D., says the company has
supplied experimental antiviral remdesivir to a small number of patients
infected with 2019-nCoV, the coronavirus causing the current outbreak,
on an emergency basis since there are no approved treatments for the
respiratory ailment.
It is working with Chinese health authorities on a
clinical trial to determine the safety and efficacy of the nucleotide
analog (it is being developed to treat infections from Ebola and Marburg
viruses). It is also expediting laboratory testing of the drug against
2019-nCoV.
The New England Journal of Medicine reported that
the first U.S. infected person, a man in Seattle, was treated with
remdesivir on the seventh day of his hospitalization. Although he is
still an in-patient, all symptoms, except his cough (which has
improved), have resolved. The day after he received the drug, his
temperature dropped from almost 103 degrees Fahrenheit to 99.1, reaching
the normal range soon thereafter.
https://seekingalpha.com/news/3537087-gilead-advancing-experimental-antiviral-to-treat-coronavirus-infection
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.